Listen to interview with host Eric Michaels and guest Dr. Nick Bott discuss the following:
- What is Neurotrack? What is the company’s mission?
- What does it do - i.e. its technology?
- Why is lifestyle change important in Alzheimer’s Prevention & what is the impact lifestyle changes like diet, exercise and social interaction, can have on a person’s memory health?
- With the industry emphasis on the role pharmaceuticals could play in the preservation of cognitive health and treatment of cognitive decline, why focus on lifestyle changes?
- How has Neurotrack been working to bring their product to market?
- Where do you see the biggest opportunities and biggest challenges in the adoption of technology like Neurotrack’s memory health platform?
- What’s next for the company? Where are you investing your resources and what strategic partnerships are you seeking to develop?
- What tips do you have for people who are concerned about their long term cognitive health? How can they take control of their memory health today?
Dr. Nick Bott received his BA in International Relations at Stanford University focusing on the psychology of religious and political violence. His interests in the role of spirituality and psychological health led him to complete his M.Div., and subsequently served as an associate pastor for two years.
He returned to the Bay Area for doctoral work in clinical psychology and neuropsychology at the PGSP - Stanford Consortium. Nick completed his clinical internship at the Palo Alto VA Health Care System as the resident neuropsychology intern. As a clinician and clinical researcher Nick has trained at the Palo Alto VA, Stanford University School of Medicine, and UCSF. His dissertation, in partnership with Stanford's D.School, demonstrated the efficacy of an intervention to increase creative production, with concomitant gains in information processing.
His research in older adult populations has focused on age-related and pathological cognitive decline and prevention through the identification of factors associated with successful cognitive aging trajectories, as well as the validation of digital assessments of cognition in clinical populations. He is excited by opportunities to translate cutting edge clinical research into scalable and affordable interventions to reduce cost and improve care for older adults experiencing cognitive decline.